Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Dosing

被引：0
|
作者：
Kavanaugh, Arthur [1 ]
McInnes, Iain B. [2 ]
Mease, Philip J. [3 ]
Hall, Stephan [4 ]
Chinoy, Hector [5 ]
Kivitz, Alan J. [6 ]
Patekar, Manmath [7 ]
Wang, Zailong [8 ]
Mpofu, Shephard [9 ]
机构：
[1] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[2] Univ Glasgow, Immunol Infect & Inflammat, Glasgow, Lanark, Scotland
[3] Swedish Med Ctr, Rheumatol Res, Seattle, WA USA
[4] Monash Univ, Melbourne, Vic 3004, Australia
[5] Univ Manchester, Manchester, Lancs, England
[6] Altoona Ctr Clin Res, Duncansville, PA USA
[7] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Pharma AG, Basel, Switzerland
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2146
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Efficacy and Safety Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
    Baeten, Dominique
    Braun, Jurgen
    Sieper, Joachim
    Dougados, Maxime
    Deodhar, Atul A.
    Baraliakos, Xenofon
    Porter, Brian
    Gong, Yankun
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [22] SUBCUTANEOUS SECUKINUMAB PROVIDES SUSTAINED INHIBITION OF RADIOGRAPHIC PROGRESSION IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM A PHASE 3 STUDY
    Mease, Philip
    van der Heijde, Desiree
    Landewe, Robert
    Mpofu, Shephard
    Rahman, Proton
    Tahir, Hasan
    Singhal, Atul
    Boettcher, Elke
    Navarra, Sandra
    Zhu, Xuan
    Readie, Aimee
    Abrams, Ken
    Pricop, Luminita
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S10 - S10
  • [23] Subcutaneous Secukinumab Provides Sustained Inhibition of Radiographic Progression in Patients with Active Psoriatic Arthritis: 52-Week Results from a Phase 3 Study
    Mease, Philip J.
    van der Heijde, Desiree
    Landewe, Robert B. M.
    Mpofu, Shephard
    Rahman, Proton
    Tahir, Hasan
    Singhal, Atul
    Bottcher, Elke
    Navarra, Sandra V.
    Zhu, Xuan
    Readie, Aimee
    Pricop, Luminita
    Abrams, Ken
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [24] SECUKINUMAB IMPROVES SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY USING A SUBCUTANEOUS DOSING REGIMEN (FUTURE 2)
    McInnes, I. B.
    Mease, P.
    Kirkham, B.
    Kavanaugh, A.
    Ritchlin, C.
    Rahman, P.
    Van der Heijde, D.
    Landewe, R.
    Conaghan, P. G.
    Gottlieb, A. B.
    Richards, H.
    Ligozio, G.
    Pricop, L.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 352 - 353
  • [25] Continued Improvement of Signs and Symptoms in Patients with Active Psoriatic Arthritis: Week 52 Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study.
    Kavanaugh, Arthur
    McInnes, Iain B.
    Gottlieb, Alice B.
    Puig, Lluis
    Rahman, Proton
    Ritchlin, Christopher T.
    Li, Shu
    Wang, Yuhua
    Doyle, Mittie K.
    Mendelsohn, Alan M.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (12): : 4168 - 4168
  • [26] CONTINUED IMPROVEMENT OF SIGNS AND SYMPTOMS IN USTEKINUMAB-TREATED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: WEEK 52 RESULTS OF A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Kavanaugh, A.
    McInnes, I. B.
    Gottlieb, A. B.
    Puig, L.
    Rahman, P.
    Ritchlin, C.
    Li, S.
    Wang, Y.
    Doyle, M.
    Mendelsohn, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 674 - 675
  • [27] Continued improvement of signs and symptoms in ustekinumab-treated patients with active psoriatic arthritis: week 52 results of a phase 3, multicenter, double-blind, placebo-controlled study
    Puig, L.
    Kavanaugh, A.
    McInnes, I. B.
    Gottlieb, A. B.
    Rahman, P.
    Ritchlin, C.
    Li, S.
    Wang, Y.
    Doyle, M. K.
    Mendelsohn, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 : 53 - 53
  • [28] Anti-Interleukin 17A Monoclonal Antibody Secukinumab Reduces Signs and Symptoms of Psoriatic Arthritis in a 24-Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
    McInnes, I.
    Sieper, J.
    Braun, J.
    Emery, Paul
    van der Heijde, D.
    Isaacs, J.
    Dahmen, G.
    Wollenhaupt, J.
    Schulze-Koops, H.
    Gsteiger, S.
    Bertolino, A.
    Hueber, W.
    Tak, P. P.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S306 - S306
  • [29] Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: 16-and 52-Week Results from a Randomized, Double-Blind, Phase 3 Study
    Kivitz, Alan
    Sedova, Liliana
    Churchill, Melvin
    Kotha, Roshan
    Singhal, Atul
    Torres, Alexander
    Valenzuela, Guillermo
    Whelan, Sarah
    Dumortier, Thomas
    Zhu, Xuan
    Martin, Ruvie
    Pricop, Luminita
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1557 - 1560
  • [30] Maintenance Of Efficacy and Safety Of Ustekinumab In Patients With Active Psoriatic Arthritis Despite Prior Conventional Nonbiologic and Anti-TNF Biologic Therapy: 1-year Results Of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial
    Ritchlin, Christopher T.
    McInnes, Iain B.
    Kavanaugh, Arthur
    Puig, Lluis
    Rahman, Proton
    Brodmerkel, Carrie
    Li, Shu
    Shen, Yaung-Kaung
    Doyle, Mittie K.
    Mendelsohn, Alan M.
    Gottlieb, Alice B.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S127 - S128
12345